CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that drug candidate SRT501, when orally administered, suppressed neurological dysfunction in a preclinical model of multiple sclerosis. Kenneth Shindler, MD, PhD, Assistant Professor of Ophthalmology at the University of Pennsylvania Scheie Eye Institute and lead investigator, will present the data today at the North American Neuro-Ophthalmology Society annual meeting.
